International Assets Investment Management LLC Acquires 5,874,744 Shares of Progyny, Inc. (NASDAQ:PGNY)

International Assets Investment Management LLC increased its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 352,414.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,876,411 shares of the company's stock after acquiring an additional 5,874,744 shares during the period. Progyny makes up approximately 0.7% of International Assets Investment Management LLC's investment portfolio, making the stock its 16th biggest position. International Assets Investment Management LLC owned approximately 6.13% of Progyny worth $218,485,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Arizona State Retirement System grew its stake in Progyny by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 22,848 shares of the company's stock valued at $777,000 after acquiring an additional 330 shares in the last quarter. RiverPark Advisors LLC raised its holdings in shares of Progyny by 54.0% during the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock worth $40,000 after acquiring an additional 374 shares in the last quarter. Xponance Inc. boosted its position in Progyny by 3.6% during the third quarter. Xponance Inc. now owns 11,629 shares of the company's stock valued at $396,000 after purchasing an additional 399 shares during the last quarter. Brown Advisory Inc. raised its stake in shares of Progyny by 3.9% during the 3rd quarter. Brown Advisory Inc. now owns 10,611 shares of the company's stock worth $361,000 after purchasing an additional 403 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Progyny by 6.4% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 7,197 shares of the company's stock valued at $245,000 after acquiring an additional 431 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Buying and Selling at Progyny

In other news, Chairman David J. Schlanger sold 20,000 shares of the business's stock in a transaction on Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the sale, the chairman now owns 86,312 shares in the company, valued at approximately $3,323,012. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Chairman David J. Schlanger sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the sale, the chairman now owns 86,312 shares of the company's stock, valued at $3,323,012. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Michael E. Sturmer sold 2,260 shares of the business's stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $40.00, for a total value of $90,400.00. Following the completion of the transaction, the president now directly owns 158,532 shares in the company, valued at $6,341,280. The disclosure for this sale can be found here. Insiders have sold 125,030 shares of company stock worth $4,714,385 over the last three months. Company insiders own 12.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $48.00 price target on shares of Progyny in a research report on Wednesday, February 28th. Leerink Partnrs restated an "outperform" rating on shares of Progyny in a report on Monday, February 26th. SVB Leerink started coverage on Progyny in a research note on Monday, February 26th. They issued an "outperform" rating and a $49.00 price objective on the stock. KeyCorp decreased their target price on Progyny from $45.00 to $43.00 and set an "overweight" rating for the company in a research note on Wednesday, February 28th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $46.00 price target on shares of Progyny in a research report on Wednesday, April 17th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $48.30.

Progyny Price Performance

Shares of NASDAQ PGNY traded down $0.35 during trading hours on Friday, reaching $31.72. The stock had a trading volume of 760,431 shares, compared to its average volume of 781,598. The business's fifty day moving average is $35.24 and its two-hundred day moving average is $35.58. Progyny, Inc. has a twelve month low of $29.44 and a twelve month high of $44.95. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 51.16, a PEG ratio of 1.34 and a beta of 1.51.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million during the quarter, compared to analysts' expectations of $274.08 million. During the same quarter last year, the company earned $0.03 earnings per share. The company's revenue for the quarter was up 26.0% compared to the same quarter last year. Sell-side analysts forecast that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.